Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting
The poster presentation (Poster #25, Abstract 7033, Hall A), titled “Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission,” will be available on the Sunesis website at www.sunesis.com, following the
For the study, researchers evaluated records from 4,382 patients with AML who had proceeded to allogeneic transplantation to understand comparative survival between those in complete remission following additional salvage therapy and those receiving prompt HCT without achieving complete remission or in first relapse following primary induction. Of the 4,382 patients, 1,440 had transplantation in primary induction failure (PIF), 1,256 were first relapse (Rel1), and 1,986 had achieved a second complete remission (CR2). Baseline characteristics were similar in the three disease status groups.
The results showed that more patients who had achieved CR2 had de novo AML, a longer duration of a first complete remission (CR1), and were more likely to report performance scores of 90 or 100. Adverse cytogenetics were more common in PIF patients and duration of CR1 was shorter in patients with Rel1 than in those with CR2. Mortality was higher for HCT in Rel1 compared to CR2 regardless of CR1 duration (RR 1.65, p < 0.0001). Similarly, mortality was higher for HCT in PIF compared to CR2 with CR1 duration < 6 (RR 1.26, p < 0.0001), 6-12 (RR 1.60, p < 0.0001) and > 12 months (RR 2.24, p < 0.0001). The probabilities of overall survival by disease status at 6 months are: CR2 73 (71-75)%; Rel1 53 (50-55)%; PIF 58 (56-61)%; and at 2 years, CR2 50 (48-52)%; REL1 27 (24-29)%; PIF 29 (27-32)%.
The data suggest that patients in remission fare better following HCT than those who receive transplant without having achieved CR, and that the ability to achieve remission is a powerful prognostic marker.
“These data point to the importance of achieving remission as an indicator of prognosis after HCT for patients with relapsed/refractory AML, and underscore the need for an effective salvage therapy,” said
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis' corporate objectives, including the anticipated progress and potential approval of vosaroxin by the EMA, potential ex-US partnership, and the expected progress in its kinase inhibitor pipeline. Words such as “prospects,” “look forward,” "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis may not be able to receive regulatory approval of vosaroxin in the U.S. or
About CIBMTR® (
A research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the
Investor and Media Inquiries:
David Pitts Argot Partners212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc.650-266-3717